- Home
- GF vs MIST Comparison
GF vs MIST Comparison
Compare GF & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GF | MIST |
|---|---|---|
| Founded | 1990 | 2003 |
| Country | Germany | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.1M | 163.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GF | MIST |
|---|---|---|
| Price | $10.89 | $2.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 28.1K | ★ 3.4M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.38 | $0.63 |
| 52 Week High | $9.41 | $2.77 |
Technical Indicators
Market Signals| Indicator | GF | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 53.56 | 68.21 |
| Support Level | $10.60 | $2.52 |
| Resistance Level | $10.99 | $2.75 |
| Average True Range (ATR) | 0.14 | 0.19 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 90.32 | 80.22 |
Price Performance
Historical ComparisonAbout GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).